Fig. 4From: Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort studyThe frequency of patients relapsing to CM (A) and MO (B) MMDs in the three months of mAbs anti-CGRP pathway discontinuationBack to article page